Gemcitabine hydrochloride is under clinical development by RenovoRx and currently in Phase III for Pancreatic Cancer. According to GlobalData, Phase III drugs for Pancreatic Cancer have a 22% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Gemcitabine hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gemcitabine hydrochloride overview
RenovoGem is under development for the treatment of locally advanced pancreatic cancer (LAPC), bile duct cancer (extrahepatic cholangiocarcinoma-eCCA), lung cancer, uterine tumors, and glioblastoma. It is administered through intraarterial and intravenous route and acts by targeting ribonucleoside diphosphate reductase subunit M1. RenovoGem is a combination of gemcitabine and the patented delivery system, RenovoCath. The drug candidate is being developed based on RenovoTAMP-Trans-arterial micro-perfusion therapy platform.
See Also:
RenovoRx overview
RenovoRx is a medical device company. The company develops solutions for targeted delivery of diagnostic, therapeutic agents and chemotherapeutic drugs targeting peripheral vascular system. It’s proprietary Trans-Arterial Micro-Perfusion (TAMP), technology platform provides chemotherapy for the treatment of solid tumors in the peripheral system. RenovoRx lead product RenovoCath, a medical device system with dual-balloon infusion catheter that delivers intra-arterial chemotherapy directly to the tumor. It also investigating TIGeR-PaC, a systemic chemotherapy for pancreatic cancer. RenovoRx is headquartered in Los Altos, California, the US.
For a complete picture of Gemcitabine hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
